<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26646670</article-id><article-id pub-id-type="pmc">4672547</article-id><article-id pub-id-type="publisher-id">1094</article-id><article-id pub-id-type="doi">10.1186/s13063-015-1094-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Effects of high-intensity aerobic exercise on psychotic symptoms and neurocognition in outpatients with schizophrenia: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Engh</surname><given-names>John A.</given-names></name><address><email>john.engh@medisin.uio.no</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Andersen</surname><given-names>Eivind</given-names></name><address><email>Eivind.andersen@hbv.no</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Holmen</surname><given-names>Tom L.</given-names></name><address><email>Tom.holmen@siv.no</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Martinsen</surname><given-names>Egil W.</given-names></name><address><email>e.w.martinsen@medisin.uio.no</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Mordal</surname><given-names>Jon</given-names></name><address><email>Jon.mordal@siv.no</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Morken</surname><given-names>Gunnar</given-names></name><address><email>Gunnar.morken@ntnu.no</email></address><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Egeland</surname><given-names>Jens</given-names></name><address><email>jens.egeland@siv.no</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Division of Mental Health and Addiction, Vestfold Hospital Trust, T&#x000f8;nsberg, Norway </aff><aff id="Aff2"><label/>Faculty of Humanities and Education, Department of Practical, Physical and Aesthetic Education, Buskerud and Vestfold University College, Borre, Norway </aff><aff id="Aff3"><label/>Division of Mental Health and Addiction, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway </aff><aff id="Aff4"><label/>Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway </aff><aff id="Aff5"><label/>Department of Psychiatry, St. Olav&#x02019;s University Hospital, Trondheim, Norway </aff><aff id="Aff6"><label/>Department of Psychology, University of Oslo, Oslo, Norway </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>557</elocation-id><history><date date-type="received"><day>15</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Engh et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The focus in recent years on physical inactivity and metabolic disturbances in individuals with schizophrenia raises the question of potential effects of physical activity. Physical activity has shown beneficial effects on cognition in healthy older individuals as well as on symptom severity in depression. However, opinions diverge regarding whether aerobic high-intensity interval training reduces cognition and key symptoms in schizophrenia.&#x000a0;The main objective for the trial is to investigate the potential effects of aerobic high-intensity interval training on neurocognitive function and mental symptoms in outpatients with schizophrenia.</p></sec><sec><title>Methods/Design</title><p>The trial is designed as a randomized controlled, observer-blinded clinical trial. Patients are randomized to 1 of 2 treatment arms with 12-week duration: aerobic high-intensity interval training or computer gaming skills training. All participants also receive treatment as usual. Primary outcome measure is neurocognitive function. Secondary outcome measures will be positive and negative symptoms, wellbeing, tobacco-smoking patterns and physiological/metabolic parameters. Patient recruitment takes place in catchment area-based outpatient clinics.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02205684">NCT02205684</ext-link>. Registered 29 July 2014.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>High-intensity interval training</kwd><kwd>Schizophrenia</kwd><kwd>Psychosis</kwd><kwd>Neurocognition</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Schizophrenia is a severe mental illness characterized by delusions and hallucinations (i.e. positive symptoms), affect flattening, poverty of speech, lack of motivation and social withdrawal (i.e. negative symptoms) and cognitive impairment, making it one of the leading causes of disability in the age group 15&#x02013;44 years [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>People with schizophrenia are more likely to smoke [<xref ref-type="bibr" rid="CR4">4</xref>], to be physically inactive [<xref ref-type="bibr" rid="CR5">5</xref>], suffer from malnutrition due to an unhealthy diet [<xref ref-type="bibr" rid="CR6">6</xref>] and have low cardiorespiratory fitness (CRF) [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. They commonly also suffer from comorbid psychiatric disorders such as depression as well as substance misuse [<xref ref-type="bibr" rid="CR10">10</xref>] and manifest multiple somatic comorbidities [<xref ref-type="bibr" rid="CR11">11</xref>]. Compared to healthy individuals there is a 2.5 to 4.0-fold increase in prevalence of the metabolic syndrome [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>] and a 20&#x000a0;% reduction in life expectancy in individuals with schizophrenia.</p><p>Antipsychotic medication is a cornerstone in the treatment of schizophrenia, substantially reducing symptom severity and relapses [<xref ref-type="bibr" rid="CR15">15</xref>]. However, antipsychotics are most effective in reducing positive symptoms, and they have minimal effect on negative symptoms or cognitive function [<xref ref-type="bibr" rid="CR16">16</xref>]. Psychosocial interventions (e.g. cognitive behavior therapy, cognitive remediation therapy, family psychoeducation, social skills training, supported employment) are usually provided in addition to pharmacological treatment and play an important role in the treatment of schizophrenia, especially in improving daily life functioning.</p><p>Among healthy individuals, physical activity has positive effects on physical health, mental health and cognition. Moreover, positive effects of physical activity have also been described for persons with mental disorders, such as depression [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. High-intensity interval training is shown to increase CRF and reduce the risk of various somatic illnesses [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] and is established as a safe and useful exercise method. For people with schizophrenia evidence is sparse with regard to the effect of physical activity, in particular on post-exercise psychological states or neurocognition. A recent randomized controlled trial (RCT) investigated the effect of an aerobic exercise program in 33 individuals with schizophrenia (aerobic exercise, <italic>n</italic>&#x02009;=&#x02009;16; treatment as usual, <italic>n</italic>&#x02009;=&#x02009;17) [<xref ref-type="bibr" rid="CR23">23</xref>]. After completion of the 12-week exercise program (1&#x000a0;hour each session, 3 times weekly) the aerobic exercise group showed a significant improvement compared to the control group. The effects of combined interventions were examined in a non-randomized study of 43 individuals with schizophrenia [<xref ref-type="bibr" rid="CR24">24</xref>]. The participants were exposed to either endurance training (<italic>n</italic>&#x02009;=&#x02009;22) or a control condition playing table soccer (<italic>n</italic>&#x02009;=&#x02009;21). During the last half of the 12-weeks intervention the individuals in both groups also attended a cognitive remediation program. Significant improvements were found in short-term and long-term verbal memory and cognitive flexibility from the start of the combined intervention at week 6 to the end of the 3-month training period in the group exposed to endurance training augmented with cognitive remediation. However, conclusions concerning the effects of each component in the combined intervention are hard to draw due to the design of the study.</p><p>Recent reviews have called for well-designed studies to explore these important topics further [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Interpretation of previous studies investigating effects of regular sport activities lasting for weeks or months have been hampered by small sample sizes [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. In the largest study to date, 20 patients with schizophrenia met compliance demands and received exercise therapy 1 to 2&#x000a0;hours a week for 6&#x000a0;months in the experimental group. When compared to 19 patients in the control condition receiving occupational therapy [<xref ref-type="bibr" rid="CR8">8</xref>] significant effects were found on positive and depressive symptoms, as well as trend level decrease for negative symptoms in per protocol analyses. The total attrition rate was 38&#x000a0;%, and in the intention-to-treat analysis no significant effects were found.</p><p>The cardiovascular fitness hypothesis [<xref ref-type="bibr" rid="CR31">31</xref>] suggests that CRF is a physiological mediator that explains the various mental health benefits of physical activity. In regard to cognitive functions, CRF might be more beneficial for individuals with limits on their cognitive reserves [<xref ref-type="bibr" rid="CR32">32</xref>], such as people with schizophrenia. A finding of exercise-induced increase in hippocampal volume in patients with schizophrenia and a positive correlation of volume increase and short-term memory improvement supports this hypothesis [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>Low CRF increases the risk of cardiovascular disease (CVD) [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], which is the largest single cause of death in schizophrenia [<xref ref-type="bibr" rid="CR36">36</xref>]. This, taken together with an unhealthy lifestyle, underscores the need for multi-disciplinary treatment and underlines the need for addressing physical activity and, in particular, high-intensity interval training, which is more effective than moderate intensity exercise in increasing CRF in the short term [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Many exercise intervention studies for persons with mental disorders have methodological limitations, which makes it difficult to draw firm conclusions. The most common limitations are small sample sizes, that the randomization process has not been undertaken at a site remote from where the intervention takes place, lack of blinded assessment of outcome, imprecise assessments (if any) of CRF, low adherence to the exercise protocols, lack of long- term follow-up assessment, and not analyzing the data according to the intention-to-treat principle [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>There is currently insufficient evidence to know whether regular high-intensity interval training reduces key symptoms in schizophrenia. Studies with larger sample sizes comprised of participants adhering to the exercise protocol are needed.</p><p>We aim to conduct a trial where these methodological considerations are addressed by comparing a 12-week aerobic high-intensity interval training (HIIT) program to skills training of the same duration, with regard to: 1) aspects of cognitive function, especially memory, attention and executive function, and 2) psychiatric symptom load (negative and positive symptoms) and wellbeing. Post-treatment improvement in cognition and psychotic symptoms are anticipated. We hypothesize that the individuals in the Exercise Group (EG) will perform better than individuals in the Computer Skills Group (CSG) on aspects of cognitive function, especially memory, attention and executive function. In addition, we expect ameliorated positive and negative symptoms in the EG.</p><p>The effects of HIIT on maximum oxygen uptake and risk factors for CVD (i.e. tobacco- smoking, elevated blood pressure, dyslipidemia, insulin resistance and high body fat) are also subject to investigation.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Trial design</title><p>This trial is designed as a randomized controlled, parallel group, observer-blinded clinical trial (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart &#x02013; participants in the Effects of Physical Activity in Psychosis (EPHAPS) trial</p></caption><graphic xlink:href="13063_2015_1094_Fig1_HTML" id="MO1"/></fig></p><p>Participants are randomized to either a high-intensity interval group (Exercise Group, EG) or to a comparison group (Computer Gaming Skills Group, CSG). During the 12-week interventions treatment as usual is continued for all patients. Patients are assessed at the start (T<sub>0</sub>) and end of the intervention (T<sub>1</sub>) as well as at 4&#x000a0;months post-treatment (T<sub>2</sub>). The trial is observer-blinded, as measurement of psychiatric symptoms and neurocognitive function is performed by research staff blinded for group allocation. The researchers are geographically dispersed from the training facilities. When assessed after training, the participants are instructed not to disclose what activity they have taken part in. The physiological testing is performed by staff involved in delivery of the interventions and will not be blinded except at baseline. The same holds for collecting self-ratings involving measures of activity.</p></sec><sec id="Sec4"><title>Recruitment and eligibility</title><p>The participants are outpatients at the psychiatric rehabilitation clinics in T&#x000f8;nsberg (Nordre Vestfold distriktspsykiatriske senter, NVDPS) and Larvik (S&#x000f8;ndre Vestfold distriktspsykiatriske senter, SVDPS) in Vestfold County. The clinics are part of the Division of Mental Health and Addiction in Vestfold Hospital Trust, Norway. The outpatient clinics are catchment area-based and cover a total population of approximately 200,000 people. Patient inclusion started in August 2014 and will continue until October 2016. Eligible for the study are outpatients who fulfill the <italic>Diagnostic and Statistical Manual of Mental Disorders</italic> (DSM-V) criteria for schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder and schizophreniform disorder). Inclusion and exclusion criteria are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Participation will be terminated if any of the exclusion criteria occurs (for instance pregnancy) during the trial or if the participant withdraws the informed consent.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>
<italic>Inclusion criteria</italic>
</td></tr><tr><td>Age between 18 and 67</td></tr><tr><td>Understand and speak a Scandinavian language</td></tr><tr><td>Fulfill the DSM-V criteria for schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder and schizophreniform disorder)</td></tr><tr><td>
<italic>Exclusion criteria</italic>
</td></tr><tr><td>Pregnancy</td></tr><tr><td>Chest pain during exercise</td></tr><tr><td>Unstable angina pectoris</td></tr><tr><td>Recent myocardial infarction</td></tr><tr><td>Uncontrollable cardiac arrhythmia</td></tr><tr><td>Severe hypertension (&#x0003e;180/110&#x000a0;mmHg)</td></tr><tr><td>Comorbid diagnosis of mild mental retardation</td></tr><tr><td>Medical conditions incompatible with participation</td></tr></tbody></table><table-wrap-foot><p>
<italic>DSM Diagnostic and Statistical Manual of Mental Disorders</italic>
</p></table-wrap-foot></table-wrap></p><sec id="Sec5"><title>Diagnosis</title><p>The diagnoses are based on the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-V) axis I disorders [<xref ref-type="bibr" rid="CR40">40</xref>]. All interviewers engaged in diagnostics participate in supervised diagnostic evaluation meetings on a regular basis.</p></sec></sec><sec id="Sec6"><title>Intervention</title><p>The exercise sessions will be conducted at the Buskerud and Vestfold University College and the computer gaming at a local high school in T&#x000f8;nsberg. Supervision of participants in the two groups is carried out by the same personnel employed in the outpatient clinics and dedicated to the project throughout the data collection period. The time spent with activities, as well as time spent with the intervention staff, is the same in both groups, and a specific time schedule is followed by the staff to ensure that each session in the exercise and comparison groups last 45&#x000a0;minutes. Participants in both groups are also accompanied by the project personnel during transportation, during the sessions of the intervention and during breaks.</p><p>The exercise sessions consist of supervised walking/running on a treadmill twice per week for 12&#x000a0;weeks. Each session will have the following structure; 8-minute warm-up, followed by 4x4 minute intervals with 85&#x02013;95&#x000a0;% of maximum heart rate, with active pauses of 3&#x000a0;minutes walking/running at approximately 70&#x000a0;% of maximum heart rate. Heart rate will be measured and controlled continuously throughout the exercise session by research personnel with a heart rate monitor (RCX3 heart monitor from Polar (Polar Electro Oy, 90440 Kempele, Finland)) to ensure that the participants intervals and active pauses are performed with the desired intensity. The exercise session will end with a 5-minute cool-down period. The goal is to have the participants adhere to the protocol. However, we realize that some participants might have difficulties with this intensive program in the beginning of the intervention, and, thus, the protocol will be individualized and progressive both in terms of the number of intervals and the intensity. This high-intensity exercise performed as 4x4 minute intervals has previously been shown to be feasible, safe and effective for individuals with schizophrenia [<xref ref-type="bibr" rid="CR41">41</xref>] and other clinical populations [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Participants in the comparison group take part in sessions performing computer-simulated sports activities (Nintendo Wii Sports (Nintendo, Frankfurt am Main, Germany) tennis, baseball, golf, bowling). Physiological responses (i.e. oxygen consumption, cardiac output, metabolic rate) of Nintendo Wii tennis (and baseball) has shown to be lower than brisk treadmill walking when tested in bouts of 10&#x000a0;minutes [<xref ref-type="bibr" rid="CR42">42</xref>]. Through comparing neurocognitive and symptom scores in a group that is physically active with the performance of a group that simulates such activity, we expect to be able to extract the net effect of high-intensity exercise. Changes in simulated sports skills are monitored and continuous feedback is given to the participants by supervising personnel.</p></sec><sec id="Sec7"><title>Treatment as usual</title><p>All participants are registered outpatients at the psychiatric rehabilitation clinics in T&#x000f8;nsberg (NVDPS) or Larvik (SVDPS) in Vestfold County and receive individual treatment during project participation. The treatment is based on appointments at the clinic and/or home visits, and may include pharmacological treatment, individual psychotherapy, family interventions, and general psychosocial support through extensive collaboration with primary care health services. Episodes of illness exacerbation may require acute or planned admittance to local or county-level inpatient units, usually of short-term duration, while remaining registered at the outpatient clinic and continuing project participation.</p></sec><sec id="Sec8"><title>Feasibility study</title><p>A feasibility study was conducted from November 2013 through January 2014. Participants were outpatients at NVDPS T&#x000f8;nsberg and had present or previous psychotic symptoms. Apart from minor alterations, the same study protocol was followed as in the main trial. The intervention period was, however, considerably shorter, ranging from 3 to 6&#x000a0;weeks. Group assignment was not randomized in the feasibility study, and the raters were not blinded. Ten patients, 6 men and 4 women, aged 22&#x02013;64 years (mean age 41) completed the study; 6 in the EG and 4 in the comparison group. The main purpose of the feasibility study was to gain experience with practical aspects of the protocol, evaluating its viability through particular focus on feedback from participants.</p></sec><sec id="Sec9"><title>Assessments</title><p>Participants will be assessed at three time points. The content of the assessments are outlined in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The first assessment occurs at baseline (T<sub>0</sub>) prior to randomization, because information from the baseline assessment is needed for validation of the inclusion and exclusion criteria and required for the stratification. The second assessment takes place immediately after completion of the intervention (T<sub>1</sub>). Longer-term outcomes or possible delayed effects not evident already at intervention cessation are tested in the third assessment 4&#x000a0;months post-treatment (T<sub>2</sub>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Assessments in the Effects of PHysical Activity in PSychosis (EPHAPS) trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Enrollment</th><th>Baseline</th><th>Randomization</th><th>Follow-up 1</th><th>Follow-up 2</th></tr><tr><th>TIME POINT</th><th/><th>T<sub>0</sub>
</th><th>0</th><th>T<sub>1 12 weeks</sub>
</th><th>T<sub>2 28 weeks</sub>
</th></tr></thead><tbody><tr><td>ENROLLMENT</td><td/><td/><td/><td/><td/></tr><tr><td>Eligibility screen</td><td>X</td><td/><td/><td/><td/></tr><tr><td>Informed consent</td><td>X</td><td/><td/><td/><td/></tr><tr><td>Allocation</td><td/><td/><td>X</td><td/><td/></tr><tr><td>INTERVENTIONS</td><td/><td/><td/><td/><td/></tr><tr><td>Exercise Group (EG)</td><td/><td/><td colspan="2">&#x0003e;---------------&#x0003c;</td><td/></tr><tr><td>Computer Gaming Skills Group (CSG)</td><td/><td/><td colspan="2">&#x0003e;---------------&#x0003c;</td><td/></tr><tr><td colspan="6">ASSESSMENTS</td></tr><tr><td colspan="6">General assessments</td></tr><tr><td>Sociodemographic data</td><td/><td>X</td><td/><td/><td/></tr><tr><td>Changes in employment status</td><td/><td/><td/><td>X</td><td>X</td></tr><tr><td>Information on tobacco, dietary habits and current level of physical activity</td><td/><td>X</td><td/><td/><td/></tr><tr><td>Changes in use of tobacco, dietary habits, medication</td><td/><td/><td/><td>X</td><td>X</td></tr><tr><td colspan="6">Somatic health</td></tr><tr><td>Physical examination: height; electrocardiography (ECG); medication record</td><td/><td>X</td><td/><td/><td/></tr><tr><td>Weight, waist circumference, blood pressure</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Changes in medication</td><td/><td/><td/><td>X</td><td>X</td></tr><tr><td>Body composition assessment (bioelectrical impedance analysis/Tanita-weight)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Blood analyses: glucose, HbA1c, C-peptide, lipids (total cholesterol, HDL, LDL, TGA), homocystein, prolactin, T4, TSH, BDNF</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Spirometry (pulmonary function test)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td colspan="6">Cardiorespiratory fitness, physical activity and sleeping habits</td></tr><tr><td>Maximal oxygen consumption</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>ActiGraph accelerometers (4&#x000a0;days)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Attitudes towards physical activity (PA)</td><td/><td>X</td><td/><td/><td/></tr><tr><td>Change in attitudes towards PA (two selected items from Attitudes towards PA)</td><td/><td/><td/><td>X</td><td>X</td></tr><tr><td>International Physical Activity Questionnaire (IPAQ)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Assessment of insomnia: Insomnia Severity Index (ISI)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td colspan="6">Psychoactive substance use</td></tr><tr><td>Selected parts of European Addiction Severity Index (EuropASI)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>SCID section E</td><td/><td>X</td><td/><td/><td/></tr><tr><td>Alcohol and Drug Use Disorder Identification Test (AUDIT and DUDIT)</td><td/><td>X</td><td/><td/><td/></tr><tr><td>Alcohol and Drug Use Scale (AUS and DUS)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Fagerstr&#x000f6;m test for Nicotine Dependence (FTND)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Saliva samples for assessing recent intake of tobacco, alcohol, illegal drugs and legal medication with abuse potential</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td colspan="6">Neurocognitive tests</td></tr><tr><td>General Ability Index (GAI, Wechsler Adult Intelligence Scale-version 4)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>The Emotional Biological Motion Test</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Matrics Consensus Cognitive Battery (MCCB)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td colspan="6">Diagnostics/symptoms/wellbeing</td></tr><tr><td>The Structural Clinical Interview DSM-IV for axis I disorders (SCID-I)</td><td/><td>X</td><td/><td/><td/></tr><tr><td>The Positive and Negative Syndrome Scale (PANSS)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>The Psychotic Symptom Rating Scale (PSYRATS)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>The revised Beliefs About Voices Questionnaire (BAVQ)</td><td/><td>X</td><td/><td/><td/></tr><tr><td>Positive and Negative Affects Schedule (PANAS)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Depression: Calgary Depression Scale for Schizophrenia (CDSS)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>WHO-5 Well-Being Index</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Self-esteem (Ad Morrison)</td><td/><td/><td/><td/><td/></tr><tr><td>Clinical Global Impression Scale (CGI)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td colspan="6">Psychosocial functioning</td></tr><tr><td>Global Assessment of Functioning (GAFs and GAFf)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Quality of Life (Strauss Carpenter Level of Function (SCLOF))</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td colspan="6">Insight/adherence/apathy</td></tr><tr><td>Insight of illness: Birchwood Insight Scale; cognitive insight: Beck Cognitive Insight Scale</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Adherence to treatment: The Believes about Medicines Questionnaire (BMQ)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Apathy: Apathy Evaluation Scale (AES)</td><td/><td>X</td><td/><td>X</td><td>X</td></tr></tbody></table><table-wrap-foot><p>The table depicts specific time points in the trial for enrolment, intervention (groups and duration), and the assessments</p><p>
<italic>BDNF</italic> brain-derived neurotropic factor, <italic>HbA1c</italic> glycosylated hemoglobin, <italic>HDL</italic> high-density lipoprotein, <italic>LDL</italic> low-density lipoprotein, <italic>T4</italic> thyroxine, <italic>TGA</italic> triglycerides, <italic>TSH</italic> thyroid stimulating hormone</p></table-wrap-foot></table-wrap></p><p>Neurocognitive function is the primary outcome in the trial. Secondary outcome measures are positive and negative symptoms, wellbeing, as well as smoking habits, and somatic health parameters such as pulmonary function, body mass composition (e.g. body fat, bone mass), blood pressure, abdominal circumference, serum lipids, blood glucose. Brain-derived neurotrophic factor (BDNF), an important biomarker for neuroplasticity that seems to be upregulated after physical activity in schizophrenia [<xref ref-type="bibr" rid="CR23">23</xref>] is also a secondary outcome measure. The changes in symptom level, wellbeing, neurocognitive scores and physiological (e.g. maximum oxygen uptake) and metabolic indices are assessed from T<sub>0</sub> to T<sub>1</sub> and from T<sub>1</sub> to T<sub>2</sub>.</p><sec id="Sec10"><title>Symptoms, affect and wellbeing</title><p>Psychosis symptoms are assessed using the Positive and Negative Syndrome Scale for Schizophrenia [<xref ref-type="bibr" rid="CR43">43</xref>]. Characteristics of delusions and hallucinations are specified using The Psychotic Symptom Rating Scale (PSYRATS, [<xref ref-type="bibr" rid="CR44">44</xref>]), also targeting the distress dimension of these symptoms at baseline and changes therein between T<sub>0</sub> and T<sub>1</sub> and between T<sub>1</sub> and T<sub>2</sub> respectively. For endorsement of patients&#x02019; beliefs, emotions and behaviour related to auditory hallucinations, the revised Beliefs About Voices Questionnaire (BAVQ-R, [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]) is applied. Participants&#x02019; depressive thinking is assessed by the Calgary Depression Scale for Schizophrenia (CDSS) [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p>The degree of positive feelings towards oneself, life and future is not necessarily dependent on the occurrence and intensity of symptoms, even in the realm of severe, psychotic disorders. The dominating emotional tone of the present is assessed by The Positive and Negative Affect Schedule (PANAS), comprised of two statistically largely independent scales [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. The self-report is administered to all patients in both intervention groups at T<sub>0</sub>, T<sub>1</sub> and T<sub>2</sub>, and, for measuring possible immediate effects, mid-intervention, after completing scheduled activity on a particular day, in addition to the PANAS assessment immediately after neurocognitive testing at T<sub>2</sub>. Self-esteem is assessed using a self-rating scale (Ad Morrison). General symptoms are appraised using the Clinical Global Impression Scale (CGI, [<xref ref-type="bibr" rid="CR51">51</xref>]). Wellbeing is assessed using the 5-item self-report World Health Organization-5 (WHO-5) Well-Being Index [<xref ref-type="bibr" rid="CR52">52</xref>]. The questionnaire has previously been used to monitor treatment in affective disorders [<xref ref-type="bibr" rid="CR53">53</xref>].</p></sec><sec id="Sec11"><title>Neurocognitive tests</title><p>Neurocognition is assessed with the Matrics Consensus Cognitive Battery (MCCB), which is developed particularly for assessment of treatment changes in schizophrenia. It assesses cognitive function in seven domains, including those most probable to increase as a function of increased cardiorespiratory fitness (executive functions, attention and memory) and offers parallel forms for repetitive testing. MCCB has been used in previous studies in Norway and the Norwegian Version has retained the original psychometric properties [<xref ref-type="bibr" rid="CR54">54</xref>] with the possible exception of the test intended to measure social cognition. This subtest will be replaced by The Emotional Biological Motion Test [<xref ref-type="bibr" rid="CR55">55</xref>], which is an experimental test newly developed by leading research groups in this field. At baseline participants will be examined with 6 subtests from the Wechsler Adult Intelligence Test-version 4, resulting in a General Ability Index-score equivalent to a full scale IQ.</p></sec><sec id="Sec12"><title>Sociodemography</title><p>Basic sociodemographic data is collected, including sex, age, education, marital status, employment, living conditions, etc.</p></sec><sec id="Sec13"><title>Lifestyle</title><p>Basic lifestyle parameters are assessed, including dietary habits, daily activity level, and daily use of stimulants containing caffeine and nicotine. Psychoactive substance use is thoroughly covered; see below.</p></sec><sec id="Sec14"><title>Somatic health</title><p>A physical examination with medication record is undertaken in the trial. All participants are examined with electrocardiography (ECG). General health parameters such as weight, waist circumference and blood pressure, as well as pulmonary function and body composition are assessed. Blood samples, which encompass standard blood tests in addition to BDNF, will be collected from participants following overnight fasting at the three assessment points. For analysis of BDNF venous blood samples are collected in tubes containing ethylenediaminetetraacetic acid (EDTA). After centrifugation at 2500&#x000a0;g for 20&#x000a0;minutes, platelet-poor plasma will be isolated, aliquoted and stored at &#x02212;80&#x000a0;&#x000b0;C. At the end of data collection, all samples will be analyzed for BDNF concentrations using enzyme immunoassay at the Research Institute for Internal Medicine, Rikshospitalet, Oslo, Norway.</p></sec><sec id="Sec15"><title>Cardiorespiratory fitness, physical activity and sleeping habits</title><p>Maximal oxygen uptake (VO<sub>2max</sub>) is measured during a maximum exercise test on a treadmill using a modified Balke protocol [<xref ref-type="bibr" rid="CR56">56</xref>]. Gas exchange is sampled continuously into a mixing chamber every 30&#x000a0;s by having the participants breathe into a Hans Rudolph 2-way breathing valve (2700 series, Hans Rudolph Inc., Kansas City, MO, USA) connected to a Jaeger Oxycon Pro gas analyzer (Erich Jaeger GmbH, Hoechberg, Germany), which measures the oxygen and carbon dioxide content.</p><p>Physical activity level is measured both objectively (ActiGraph accelerometer GT3X+ (ActiGraph, Pensacola, FL, USA) worn on the hip for 4 consecutive days; 2 weekdays and 2&#x000a0;days of the weekend) and subjectively using the International Physical Activity Questionnaire (IPAQ, short form [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]). In addition, potential psychosocial mediators for change in physical activity and attitudes towards physical activity will be measured by previously developed and validated scales: social support for physical activity [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], self-efficacy and outcome expectancies and attitudes [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Sleeping habits are assessed using the ActiGraph data as well as the brief Insomnia Severity Index (ISI, [<xref ref-type="bibr" rid="CR63">63</xref>]).</p></sec><sec id="Sec16"><title>Psychoactive substance use</title><p>At baseline, a diagnostic assessment of psychoactive substance use is performed with the SCID section E (including alcohol, illegal drugs and legal drugs with abuse potential), and the severity of such use is additionally measured with the Alcohol and Drug Use Disorder Identification Tests (AUDIT [<xref ref-type="bibr" rid="CR64">64</xref>] and DUDIT [<xref ref-type="bibr" rid="CR65">65</xref>]). Assessments at 3 time points (T<sub>0</sub>/T<sub>1</sub>/T<sub>2</sub>) will include selected parts of the European Addiction Severity Index (EuropASI) [<xref ref-type="bibr" rid="CR66">66</xref>], Alcohol [<xref ref-type="bibr" rid="CR67">67</xref>] and Drug Use Scales [<xref ref-type="bibr" rid="CR68">68</xref>] (AUS and DUS respectively), Fagerstr&#x000f6;m test for Nicotine Dependence [<xref ref-type="bibr" rid="CR69">69</xref>] and saliva samples for assessing recent intake of tobacco, alcohol, illegal drugs and legal medication with abuse potential. The toxicological analyses will be performed at Division of Forensic Toxicology and Drug Abuse Research, Norwegian Institute of Public Health.</p></sec><sec id="Sec17"><title>Psychosocial functioning, adherence and insight</title><p>Strauss Carpenter Level of Functioning Scale (SCLOF) is utilized for the endorsement of patients&#x02019; social and work functioning. Global Assessment of Functioning (GAF, [<xref ref-type="bibr" rid="CR70">70</xref>]) is divided into two scales measuring symptoms (GAFs) and function (GAFf) to improve psychometric properties [<xref ref-type="bibr" rid="CR71">71</xref>]. Insight of illness (Birchwood Insight Scale, IS, [<xref ref-type="bibr" rid="CR72">72</xref>]), cognitive insight (Beck Cognitive Insight Scale, BCIS, [<xref ref-type="bibr" rid="CR73">73</xref>]) and apathy (Apathy Evaluation Scale, AES, [<xref ref-type="bibr" rid="CR74">74</xref>]) are assessed using self-rating scales.</p></sec></sec><sec id="Sec18"><title>Protocol deviations</title><p>When absent from scheduled exercise or computer gaming, the participant will be contacted and offered to participate on a following day the same week. Participants who fail to complete at least 60&#x000a0;% of the total number of intervention sessions or have not participated for more than 2 successive weeks are considered protocol violators. Participants who are unable to meet for the VO<sub>2max</sub> test within 10&#x000a0;days following the last training session will also be considered protocol violators. However, they will be allowed to stay in the study and will be tested as soon as possible, as well as invited to take part in T<sub>2</sub>. Statistical analyses will be performed both based on the principle of &#x0201c;intention-to-treat&#x0201d; including everyone regardless of protocol violations, but &#x0201c;per protocol&#x0201d; analyses will also be executed, comparing only those who completed the two treatment conditions according to the protocol.</p></sec><sec id="Sec19"><title>Sample size calculations</title><p>We assume that the outcome measures are continuous variables with a normal distribution, and two independent clinical groups are being compared. Estimates of statistical power are calculated for the primary outcome measure. The neurocognitive tests applied in the study (MCCB battery) are designed for repeated administrations to test possible treatment effects. Some improvement must be expected in both groups because of the treatment/stimulation and as retest effects (being accustomed to the test design if not the actual test material). Nevertheless, we expect that the effect size in the EG will be 0.50 standard deviations (which is a medium effect size) <italic>larger</italic> than the increase in the CSG, which given a statistical power of 0.80 and alpha of 0.05 necessitates a sample size of 55 in each group. The dropout rate in the current study after randomization and group assignment is estimated to 15&#x000a0;%. Thus, the estimate is that recruitment of 126 participants is needed to secure the participation of 55 individuals in each group. Further attrition at later stages in the study progress is accounted for by utilizing the &#x0201c;intention-to treat&#x0201d; analysis.</p></sec><sec id="Sec20"><title>Randomization and stratification</title><p>After the baseline assessments, the participants will be randomly assigned to either CSG or EG. A computerized random number generator is utilized to produce the allocation sequence. Equal distribution of participants in the two groups on CRF is ensured by stratification on expected median with regard to scores on VO<sub>2max</sub> at baseline. By varying the size of the stratification blocks, each treatment assignment remains unpredictable. Senior researchers in the project (JAE, JE) generated the randomization sequence. A dedicated project coordinator, who is not located near the participants during sessions and not concerned with outcome assessments, administers the group assignment using the method of concealed envelopes. The name, date of birth, trial number and assigned treatment is registered on a log sheet made for the participant in the trial.</p></sec><sec id="Sec21"><title>Statistical analysis</title><p>Decisions about sample size and design of the project are primarily aimed at comparing the EG with the CSG. The main statistical analyses will be variants of analyses of variance such as Multivariate ANOVA (MANOVA) to test overall group differences, repeated measures ANOVA to look for interactions between time and group (i.e. to test whether the EG have larger change between time points than CSG). Changes in outcome measures will be correlated with changes in CRF. Analysis of covariance will be used to test hypotheses whether the effect of specific variables extend beyond effects of nonspecific variables. Baseline data could be analyzed without referral to later group membership, enabling analyses of empirically derived subgroups such as participants scoring low or high on the physiological measures, or participants with or without concurrent tobacco use. Baseline data will also be analyzed with regression analyses and correlations/partial correlations controlling for potential confounding variables.</p></sec><sec id="Sec22"><title>Data storage and use of statistical tools</title><p>The data will be stored and analyzed in the Vestfold Hospital Trust using the Statistical Package for the Social Sciences (SPSS version 18.0.1, SPSS inc., Chicago, IL, USA). Data cleaning will be performed via SPSS syntax operations (SPSS Inc., Chicago, IL, USA).</p></sec><sec id="Sec23"><title>Ethical considerations</title><p>The project is approved by the Regional Ethics Committee of Southern and Eastern Norway (REK S&#x000f8;r-&#x000d8;st) under file number 2014/372/REK S&#x000d8;R-&#x000d8;ST C. Trial registration has been carried out at ClinicalTrial.gov (NCT02205684). Informed and written consent is a pre-requisite for participation. Initial information about the study will be given to eligible patients by the regular staff during a routine appointment in the outpatient clinic, or by a project co-worker. Further detailed written and oral information about the trial will then be given by the project co-worker. It will be assured that participation is voluntary, that the participants can withdraw at any time point and will receive ordinary treatment whether they choose to participate or not. If the patient understands the nature of the research and is willing to participate, he or she will be asked to sign a consent form. The interviews in the trial will be completed in several encounters with the participant, and emphasis will be put on avoiding unnecessary strain on the individual and adjustment to own preferences. Similarly, when taking part in the treatment intervention, attention will be paid to the physical fitness of the participant. Potential alteration of the intensity and frequency of the physical activity will be adjusted individually over several weeks. Participants experiencing discomfort or possible medical complications while exercising on the treadmill will receive immediate necessary examination by medical staff in the unit. Positive as well as negative results will be published according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines [<xref ref-type="bibr" rid="CR75">75</xref>].</p></sec><sec id="Sec24"><title>Motivational work</title><p>Motivating patients with severe mental disorders, prone to be insufficiently physically fit to perform high-intensity interval training twice a week, is perceived a major challenge. Although the motivational work is performed by the intervention staff in informal settings when talking to participants before and after each session, as well as during transportation between their home and the project facilities, it needs to be structured and theory-based. Key constructs in social cognitive theory [<xref ref-type="bibr" rid="CR76">76</xref>] are applied (i.e. opportunities to perform physical activity; social support for physical activity; confidence to do physical activity; expected benefits and costs of performing physical activity; knowledge and skill to perform physical activity; personal goal setting and monitoring of physical activity), putting much effort in translating this knowledge into effective practices.</p></sec><sec id="Sec25"><title>Adverse events</title><p>Medical examination and ECG are performed before the exercise program starts, and all patients are evaluated as suitable for training. One potential concern might be the combination of physical exercise and medication, but there is no evidence for danger in exercising while using therapeutic doses of psychotropic medication [<xref ref-type="bibr" rid="CR77">77</xref>].</p></sec><sec id="Sec26"><title>Emergency procedures</title><p>To minimize the risk of medical emergencies, patients with a known unstable heart condition (e.g. unstable angina pectoris and recent myocardial infarction) will be excluded from the study. Also, ECG and physical examination performed by a physician are performed before inclusion in the study. Health staff with specific knowledge of cardiopulmonary resuscitation will be present at all treadmill-sessions of physical testing and exercise. In case of symptoms such as chest pain and dizziness during exercise, the session will be discontinued immediately. In case of symptoms of cardiac arrest (unresponsive person with no or abnormal breathing), cardiopulmonary resuscitation will be initiated immediately and an ambulance will be called.</p></sec></sec><sec id="Sec27" sec-type="discussion"><title>Discussion</title><p>Physical activity has been shown to reduce symptoms of depression and increase cognitive functions in other groups associated with cognitive dysfunction such as Parkinson&#x02019;s disease [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>] and old age [<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR82">82</xref>]. It is, therefore, plausible that physical activity may have beneficial effects, both on the level of mental symptoms and cognitive function in schizophrenia, but high-quality data from RCTs is lacking. In the present study high-intensity treadmill exercise for 12&#x000a0;weeks is compared to computer-based skills training, otherwise shown to have beneficial effects on cognitive function [<xref ref-type="bibr" rid="CR33">33</xref>]. Well-validated measures of the respective functional domains serve as main outcome measures and assessments are performed pre-training, immediately after completed training and 4&#x000a0;months post-treatment allowing appraisal of possible delay between increased CRF and reduced symptoms. Secondary outcome measures are related to factors reducing risk of metabolic syndrome and improving physical health. If we find that intensive exercise can reduce symptoms and increase cognitive performance, it may have implications for future treatment of patients with schizophrenia. As cognitive remediation programs so far have focused on learning techniques in a top-down fashion [<xref ref-type="bibr" rid="CR83">83</xref>], documenting possible bottom-up beneficial effects may open up new routes for helping these patients increase their cognitive functions. In regard to symptom reduction, broadening the armamentarium of methods, primarily consisting of pharmacological treatment and psychotherapy, to also contain physical activity, will be welcomed as increased CRF in general has an effect on both morbidity and mortality.</p><p>As the general optimism regarding the positive effects of physical activity on symptoms and cognition has now spread from normal aging, treatment of depression to schizophrenia, resulting in small-scale or non-systematically researched interventions, the findings of no differential increase in mental and cognitive functions, may lead to some disappointment regarding the role of physical activity in treating these elements of severe mental disorder. Early death from cardiovascular disorders and reduced function due to low cardiovascular capacity and low muscular strength are other important treatable elements of the schizophrenia group of disorders. It is important that treatment approaches are empirically-based and not merely plausible inferences from knowledge in other groups. High-intensity exercise is demanding for the patient, as well as the help-giving system. Thus, with this level of knowledge, emphasis should be placed on finding causal effects or mediating mechanisms, while the cost-effectiveness of physical activity, as a way to improve functions other than key symptoms in schizophrenia, is another important issue.</p><p>Perhaps, the greatest challenge conducting an intervention study of this kind is making the participants adhere to the demanding exercise regime. To meet this challenge, participants are given individual tutoring and motivational talks and are offered project-initiated transportation in order to increase adherence &#x02013; a support regime which is equally comprehensive in both groups. Thus, the present trial involves a support system that would not be sustainable in ordinary clinical work.</p><p>In selection of an adequate control condition, it is important for adherence to the skills training control group that both the participants and the intervention staff find the activity meaningful, and by that preventing an expectancy-related lack of effect in the comparison group.</p></sec><sec id="Sec28"><title>Trial status</title><p>The recruitment started August 2014. By April 2015 a total of 32 subjects were participating. Five subjects have dropped out of the study. The planned recruitment of 126 participants will be completed by October 2016.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AES</term><def><p>Apathy Evaluation Scale</p></def></def-item><def-item><term>ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term>AUDIT</term><def><p>Alcohol Use Disorder Identification Test</p></def></def-item><def-item><term>AUS</term><def><p>Alcohol Use Scale</p></def></def-item><def-item><term>BAVQ-R</term><def><p>The revised Beliefs About Voices Questionnaire</p></def></def-item><def-item><term>BCIS</term><def><p>Beck Cognitive Insight Scale</p></def></def-item><def-item><term>BDNF</term><def><p>brain-derived neurotrophic factor</p></def></def-item><def-item><term>BMQ</term><def><p>The Believes about Medicines Questionnaire</p></def></def-item><def-item><term>CDSS</term><def><p>Calgary Depression Scale for Schizophrenia</p></def></def-item><def-item><term>CSG</term><def><p>Computer Gaming skills Group</p></def></def-item><def-item><term>CGI</term><def><p>Clinical Global Impression Scale</p></def></def-item><def-item><term>CONSORT</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term>CRF</term><def><p>cardiorespiratory fitness</p></def></def-item><def-item><term>CVD</term><def><p>cardiovascular disease</p></def></def-item><def-item><term>DSM-V</term><def><p><italic>Diagnostic and Statistical Manual of Mental Disorders</italic></p></def></def-item><def-item><term>DUDIT</term><def><p>Drug Use Disorder Identification Test</p></def></def-item><def-item><term>DUS</term><def><p>Drug Use Scale</p></def></def-item><def-item><term>ECG</term><def><p>electrocardiogram</p></def></def-item><def-item><term>EDTA</term><def><p>ethylenediaminetetraacetic</p></def></def-item><def-item><term>EG</term><def><p>exercise group</p></def></def-item><def-item><term>EPHAPS</term><def><p>Effects of Physical Activity in PSychosis</p></def></def-item><def-item><term>EuropASI</term><def><p>European Addiction Severity Index</p></def></def-item><def-item><term>FTND</term><def><p>Fagerstr&#x000f6;m Test for Nicotine Dependence</p></def></def-item><def-item><term>GAF</term><def><p>Global Assessment of Functioning</p></def></def-item><def-item><term>GAI</term><def><p>General Ability Index</p></def></def-item><def-item><term>HIIT</term><def><p>high-intensity interval training</p></def></def-item><def-item><term>IPAQ</term><def><p>International Physical Activity Questionnaire</p></def></def-item><def-item><term>IS</term><def><p>Insight Scale</p></def></def-item><def-item><term>ISI</term><def><p>Insomnia Severity Index</p></def></def-item><def-item><term>MANOVA</term><def><p>multivariate analysis of variance</p></def></def-item><def-item><term>MCCB</term><def><p>Matrics Consensus Cognitive Battery</p></def></def-item><def-item><term>NTNU</term><def><p>Norwegian University of Science and Technology</p></def></def-item><def-item><term>NVDPS</term><def><p>Nordre Vestfold Distrikt Psykiatrisk Senter</p></def></def-item><def-item><term>PANAS</term><def><p>Positive and Negative Affects Schedule</p></def></def-item><def-item><term>PANSS</term><def><p>Positive and Negative Syndrome Scale</p></def></def-item><def-item><term>PSYRATS</term><def><p>The Psychotic Symptom Rating Scale</p></def></def-item><def-item><term>RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term>REK S&#x000f8;r-&#x000d8;st</term><def><p>Regional Ethics Committee of Southern and Eastern Norway</p></def></def-item><def-item><term>SCID-I</term><def><p>The Structural Clinical Interview DSM-IV for axis I disorders</p></def></def-item><def-item><term>SCLOF</term><def><p>Strauss Carpenter Level of Functioning Scale</p></def></def-item><def-item><term>SVDPS</term><def><p>S&#x000f8;ndre Vestfold Distrikt Psykiatrisk Senter</p></def></def-item><def-item><term>VO<sub>2max</sub></term><def><p>maximal oxygen uptake</p></def></def-item><def-item><term>WAIS</term><def><p>Wechsler Adult Intelligence Scale</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>JAE, JE, EA and JM conceived the study, acquired funding and approval of the ethics committee. These four researchers, in addition to EWM and GM contributed to study design. TLH carried out parts of the clinical testing. The manuscript has been drafted by JAE, JE, EA and JM. All authors read, worked on and approved the final manuscript.</p></fn></fn-group><ack><p>The investigators would like to give thanks to the patients participating in the feasibility study as well as the patients participating in the first part of the main trial. We owe many thanks to Therese Torgersen Bigseth and Rizwan Parvaiz in contributing to the recruitment of patients, carrying out the clinical testing, as well as to Merete R&#x000f8;nningen Bergstad, Helge Bjune, Ole Jakob Bredrup, Ellen Gurine F&#x000e6;rvik, Jan Freddy Hovland, Camilla Lahn-Johannessen, Bj&#x000f8;rn Einar Oscarsen, and Siri &#x000d8;yhus for conducting the intervention. The trial has received funding from Vestfold Hospital Trust, Norwegian Extra Foundation for Health and Rehabilitation through EXTRA funds, Norwegian Research network in Severe Mental Illness (NORSMI), NORMENT/KG Jebsen Centre for Psychosis Research, Torgeir Lindvik&#x02019;s Trust, and Civitan International.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossler</surname><given-names>W</given-names></name><name><surname>Salize</surname><given-names>HJ</given-names></name><name><surname>Van</surname><given-names>OJ</given-names></name><name><surname>Riecher-Rossler</surname><given-names>A</given-names></name></person-group><article-title>Size of burden of schizophrenia and psychotic disorders</article-title><source>Eur Neuropsychopharmacol</source><year>2005</year><volume>15</volume><fpage>399</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2005.04.009</pub-id><pub-id pub-id-type="pmid">15925493</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutz</surname><given-names>W</given-names></name></person-group><article-title>The European WHO mental health programme and the World Health Report 2001: input and implications</article-title><source>Br J Psychiatry</source><year>2003</year><volume>183</volume><fpage>73</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1192/bjp.183.1.73</pub-id><pub-id pub-id-type="pmid">12835247</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization. World Health Report</collab></person-group><source>Mental health: new understanding, New Hope</source><year>2001</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><fpage>2001</fpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCreadie</surname><given-names>RG</given-names></name></person-group><article-title>Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study</article-title><source>Br J Psychiatry</source><year>2003</year><volume>183</volume><fpage>534</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1192/bjp.183.6.534</pub-id><pub-id pub-id-type="pmid">14645025</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindamer</surname><given-names>LA</given-names></name><name><surname>McKibbin</surname><given-names>C</given-names></name><name><surname>Norman</surname><given-names>GJ</given-names></name><name><surname>Jordan</surname><given-names>L</given-names></name><name><surname>Harrison</surname><given-names>K</given-names></name><name><surname>Abeyesinhe</surname><given-names>S</given-names></name><etal/></person-group><article-title>Assessment of physical activity in middle-aged and older adults with schizophrenia</article-title><source>Schizophr Res</source><year>2008</year><volume>104</volume><issue>1-3</issue><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2008.04.040</pub-id><pub-id pub-id-type="pmid">18550338</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strassnig</surname><given-names>M</given-names></name><name><surname>Brar</surname><given-names>JS</given-names></name><name><surname>Ganguli</surname><given-names>R</given-names></name></person-group><article-title>Nutritional assessment of patients with schizophrenia: a preliminary study</article-title><source>Schizophr Bull</source><year>2003</year><volume>29</volume><issue>2</issue><fpage>393</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a007013</pub-id><pub-id pub-id-type="pmid">14552512</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heggelund</surname><given-names>J</given-names></name><name><surname>Nilsberg</surname><given-names>GE</given-names></name><name><surname>Hoff</surname><given-names>J</given-names></name><name><surname>Morken</surname><given-names>G</given-names></name><name><surname>Helgerud</surname><given-names>J</given-names></name></person-group><article-title>Effects of high aerobic intensity training in patients with schizophrenia: a controlled trial</article-title><source>Nord J Psychiatry</source><year>2011</year><volume>65</volume><issue>4</issue><fpage>269</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3109/08039488.2011.560278</pub-id><pub-id pub-id-type="pmid">21332297</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheewe</surname><given-names>TW</given-names></name><name><surname>Takken</surname><given-names>T</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>Cahn</surname><given-names>W</given-names></name><name><surname>Backx</surname><given-names>FJ</given-names></name></person-group><article-title>Effects of exercise therapy on cardiorespiratory fitness in patients with schizophrenia</article-title><source>Med Sci Sports Exerc</source><year>2012</year><volume>44</volume><issue>10</issue><fpage>1834</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1249/MSS.0b013e318258e120</pub-id><pub-id pub-id-type="pmid">22525773</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strassnig</surname><given-names>M</given-names></name><name><surname>Brar</surname><given-names>JS</given-names></name><name><surname>Ganguli</surname><given-names>R</given-names></name></person-group><article-title>Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia</article-title><source>Schizophr Res</source><year>2011</year><volume>126</volume><issue>1-3</issue><fpage>103</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2010.10.025</pub-id><pub-id pub-id-type="pmid">21146958</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ringen</surname><given-names>PA</given-names></name><name><surname>Melle</surname><given-names>I</given-names></name><name><surname>Birkenaes</surname><given-names>AB</given-names></name><name><surname>Engh</surname><given-names>JA</given-names></name><name><surname>Faerden</surname><given-names>A</given-names></name><name><surname>Vaskinn</surname><given-names>A</given-names></name><etal/></person-group><article-title>The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness</article-title><source>Acta Psychiatr Scand</source><year>2008</year><volume>118</volume><issue>4</issue><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.2008.01244.x</pub-id><pub-id pub-id-type="pmid">18759810</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheewe</surname><given-names>TW</given-names></name><name><surname>Backx</surname><given-names>FJ</given-names></name><name><surname>Takken</surname><given-names>T</given-names></name><name><surname>Jorg</surname><given-names>F</given-names></name><name><surname>van Strater</surname><given-names>AC</given-names></name><name><surname>Kroes</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trial</article-title><source>Acta Psychiatr Scand</source><year>2013</year><volume>127</volume><issue>6</issue><fpage>464</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/acps.12029</pub-id><pub-id pub-id-type="pmid">23106093</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birkenaes</surname><given-names>AB</given-names></name><name><surname>Opjordsmoen</surname><given-names>S</given-names></name><name><surname>Brunborg</surname><given-names>C</given-names></name><name><surname>Engh</surname><given-names>JA</given-names></name><name><surname>Jonsdottir</surname><given-names>H</given-names></name><name><surname>Ringen</surname><given-names>PA</given-names></name><etal/></person-group><article-title>The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study</article-title><source>J Clin Psychiatry</source><year>2007</year><volume>68</volume><issue>6</issue><fpage>917</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.4088/JCP.v68n0614</pub-id><pub-id pub-id-type="pmid">17592917</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McEvoy</surname><given-names>JP</given-names></name><name><surname>Meyer</surname><given-names>JM</given-names></name><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Nasrallah</surname><given-names>HA</given-names></name><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Sullivan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III</article-title><source>Schizophr Res</source><year>2005</year><volume>80</volume><issue>1</issue><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2005.07.014</pub-id><pub-id pub-id-type="pmid">16137860</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiskanen</surname><given-names>T</given-names></name><name><surname>Niskanen</surname><given-names>L</given-names></name><name><surname>Lyytikainen</surname><given-names>R</given-names></name><name><surname>Saarinen</surname><given-names>PI</given-names></name><name><surname>Hintikka</surname><given-names>J</given-names></name></person-group><article-title>Metabolic syndrome in patients with schizophrenia</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><issue>5</issue><fpage>575</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4088/JCP.v64n0513</pub-id><pub-id pub-id-type="pmid">12755662</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>Stroup</surname><given-names>TS</given-names></name><name><surname>McEvoy</surname><given-names>JP</given-names></name><name><surname>Swartz</surname><given-names>MS</given-names></name><name><surname>Rosenheck</surname><given-names>RA</given-names></name><name><surname>Perkins</surname><given-names>DO</given-names></name><etal/></person-group><article-title>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><issue>12</issue><fpage>1209</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa051688</pub-id><pub-id pub-id-type="pmid">16172203</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueser</surname><given-names>KT</given-names></name><name><surname>Deavers</surname><given-names>F</given-names></name><name><surname>Penn</surname><given-names>DL</given-names></name><name><surname>Cassisi</surname><given-names>JE</given-names></name></person-group><article-title>Psychosocial treatments for schizophrenia</article-title><source>Annu Rev Clin Psychol</source><year>2013</year><volume>9</volume><fpage>465</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1146/annurev-clinpsy-050212-185620</pub-id><pub-id pub-id-type="pmid">23330939</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooney</surname><given-names>GM</given-names></name><name><surname>Dwan</surname><given-names>K</given-names></name><name><surname>Greig</surname><given-names>CA</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Rimer</surname><given-names>J</given-names></name><name><surname>Waugh</surname><given-names>FR</given-names></name><etal/></person-group><article-title>Exercise for depression</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>9</volume><fpage>Cd004366</fpage><pub-id pub-id-type="pmid">24026850</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinsen</surname><given-names>EW</given-names></name></person-group><article-title>Physical activity in the prevention and treatment of anxiety and depression</article-title><source>Nord J Psychiatry</source><year>2008</year><volume>62</volume><issue>Suppl 47</issue><fpage>25</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/08039480802315640</pub-id><pub-id pub-id-type="pmid">18752115</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimer</surname><given-names>J</given-names></name><name><surname>Dwan</surname><given-names>K</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Greig</surname><given-names>CA</given-names></name><name><surname>McMurdo</surname><given-names>M</given-names></name><name><surname>Morley</surname><given-names>W</given-names></name><etal/></person-group><article-title>Exercise for depression</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>7</volume><fpage>Cd004366</fpage><pub-id pub-id-type="pmid">22786489</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craft</surname><given-names>LL</given-names></name><name><surname>Landers</surname><given-names>DM</given-names></name></person-group><article-title>The effect of exercise on clinical depression and depression resulting from mental illness: a meta-analysis</article-title><source>J Sport Exerc Psychol</source><year>1998</year><volume>20</volume><issue>4</issue><fpage>339</fpage><lpage>57</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tjonna</surname><given-names>AE</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Rognmo</surname><given-names>O</given-names></name><name><surname>Stolen</surname><given-names>TO</given-names></name><name><surname>Bye</surname><given-names>A</given-names></name><name><surname>Haram</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study</article-title><source>Circulation</source><year>2008</year><volume>118</volume><issue>4</issue><fpage>346</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.772822</pub-id><pub-id pub-id-type="pmid">18606913</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisloff</surname><given-names>U</given-names></name><name><surname>Stoylen</surname><given-names>A</given-names></name><name><surname>Loennechen</surname><given-names>JP</given-names></name><name><surname>Bruvold</surname><given-names>M</given-names></name><name><surname>Rognmo</surname><given-names>O</given-names></name><name><surname>Haram</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>24</issue><fpage>3086</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.675041</pub-id><pub-id pub-id-type="pmid">17548726</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimhy</surname><given-names>D</given-names></name><name><surname>Vakhrusheva</surname><given-names>J</given-names></name><name><surname>Bartels</surname><given-names>MN</given-names></name><name><surname>Armstrong</surname><given-names>HF</given-names></name><name><surname>Ballon</surname><given-names>JS</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><etal/></person-group><article-title>The impact of aerobic exercise on brain-derived neurotrophic factor and neurocognition in individuals with schizophrenia: a single-blind, randomized clinical trial</article-title><source>Schizophr Bull</source><year>2015</year><volume>41</volume><issue>4</issue><fpage>859</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbv022</pub-id><pub-id pub-id-type="pmid">25805886</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malchow</surname><given-names>B</given-names></name><name><surname>Keller</surname><given-names>K</given-names></name><name><surname>Hasan</surname><given-names>A</given-names></name><name><surname>D&#x000f6;rfler</surname><given-names>S</given-names></name><name><surname>Schneider-Axmann</surname><given-names>T</given-names></name><name><surname>Hillmer-Vogel</surname><given-names>U</given-names></name><etal/></person-group><article-title>Effects of endurance training combined with cognitive remediation on everyday functioning, symptoms, and cognition in multiepisode schizophrenia patients</article-title><source>Schizophr Bull</source><year>2015</year><volume>41</volume><issue>4</issue><fpage>847</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbv020</pub-id><pub-id pub-id-type="pmid">25782770</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorczynski</surname><given-names>P</given-names></name><name><surname>Faulkner</surname><given-names>G</given-names></name></person-group><article-title>Exercise therapy for schizophrenia</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><volume>5</volume><fpage>Cd004412</fpage><pub-id pub-id-type="pmid">20464730</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zschucke</surname><given-names>E</given-names></name><name><surname>Heinz</surname><given-names>A</given-names></name><name><surname>Strohle</surname><given-names>A</given-names></name></person-group><article-title>Exercise and physical activity in the therapy of substance use disorders</article-title><source>Sci World J</source><year>2012</year><volume>2012</volume><fpage>901741</fpage><pub-id pub-id-type="doi">10.1100/2012/901741</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heggelund</surname><given-names>J</given-names></name><name><surname>Kleppe</surname><given-names>KD</given-names></name><name><surname>Morken</surname><given-names>G</given-names></name><name><surname>Vedul-Kjelsas</surname><given-names>E</given-names></name></person-group><article-title>High aerobic intensity training and psychological states in patients with depression or schizophrenia</article-title><source>Front Psychiatry</source><year>2014</year><volume>5</volume><fpage>148</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2014.00148</pub-id><pub-id pub-id-type="pmid">25400592</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beebe</surname><given-names>LH</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Morris</surname><given-names>N</given-names></name><name><surname>Goodwin</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>SS</given-names></name><name><surname>Kuldau</surname><given-names>J</given-names></name></person-group><article-title>Effects of exercise on mental and physical health parameters of persons with schizophrenia</article-title><source>Issues Ment Health Nurs</source><year>2005</year><volume>26</volume><issue>6</issue><fpage>661</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1080/01612840590959551</pub-id><pub-id pub-id-type="pmid">16020076</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzaloni</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>B</given-names></name><name><surname>Melville</surname><given-names>P</given-names></name></person-group><article-title>Feasibility and effects of a group-based resistance and aerobic exercise program for individuals with schizophrenia: a multidisciplinary approach</article-title><source>Ment Health Phys Act</source><year>2009</year><volume>2</volume><issue>1</issue><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.mhpa.2008.11.001</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acil</surname><given-names>AA</given-names></name><name><surname>Dogan</surname><given-names>S</given-names></name><name><surname>Dogan</surname><given-names>O</given-names></name></person-group><article-title>The effects of physical exercises to mental state and quality of life in patients with schizophrenia</article-title><source>J Psychiatr Ment Health Nurs</source><year>2008</year><volume>15</volume><fpage>808</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2850.2008.01317.x</pub-id><pub-id pub-id-type="pmid">19012672</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aberg</surname><given-names>MA</given-names></name><name><surname>Pedersen</surname><given-names>NL</given-names></name><name><surname>Toren</surname><given-names>K</given-names></name><name><surname>Svartengren</surname><given-names>M</given-names></name><name><surname>Backstrand</surname><given-names>B</given-names></name><name><surname>Johnsson</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cardiovascular fitness is associated with cognition in young adulthood</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><issue>49</issue><fpage>20906</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1073/pnas.0905307106</pub-id><pub-id pub-id-type="pmid">19948959</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etnier</surname><given-names>JL</given-names></name><name><surname>Nowell</surname><given-names>PM</given-names></name><name><surname>Landers</surname><given-names>DM</given-names></name><name><surname>Sibley</surname><given-names>BA</given-names></name></person-group><article-title>A meta-regression to examine the relationship between aerobic fitness and cognitive performance</article-title><source>Brain Res Rev</source><year>2006</year><volume>52</volume><issue>1</issue><fpage>119</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.brainresrev.2006.01.002</pub-id><pub-id pub-id-type="pmid">16490256</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajonk</surname><given-names>FG</given-names></name><name><surname>Wobrock</surname><given-names>T</given-names></name><name><surname>Gruber</surname><given-names>O</given-names></name><name><surname>Scherk</surname><given-names>H</given-names></name><name><surname>Berner</surname><given-names>D</given-names></name><name><surname>Kaizl</surname><given-names>I</given-names></name><etal/></person-group><article-title>Hippocampal plasticity in response to exercise in schizophrenia</article-title><source>Arch Gen Psychiatry</source><year>2010</year><volume>67</volume><issue>2</issue><fpage>133</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.193</pub-id><pub-id pub-id-type="pmid">20124113</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildgust</surname><given-names>HJ</given-names></name><name><surname>Beary</surname><given-names>M</given-names></name></person-group><article-title>Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?</article-title><source>J Psychopharmacol</source><year>2010</year><volume>24</volume><issue>4 Suppl</issue><fpage>37</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1177/1359786810384639</pub-id><pub-id pub-id-type="pmid">20923919</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014; 10:425-48.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Hennekens</surname><given-names>AR</given-names></name><name><surname>Hollar</surname><given-names>D</given-names></name><name><surname>Casey</surname><given-names>DE</given-names></name></person-group><article-title>Schizophrenia and increased risks of cardiovascular disease</article-title><source>Am Heart J</source><year>2005</year><volume>150</volume><fpage>1115</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2005.02.007</pub-id><pub-id pub-id-type="pmid">16338246</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helgerud</surname><given-names>J</given-names></name><name><surname>Hoydal</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Karlsen</surname><given-names>T</given-names></name><name><surname>Berg</surname><given-names>P</given-names></name><name><surname>Bjerkaas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Aerobic high-intensity intervals improve VO2max more than moderate training</article-title><source>Med Sci Sports Exerc</source><year>2007</year><volume>39</volume><issue>4</issue><fpage>665</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1249/mss.0b013e3180304570</pub-id><pub-id pub-id-type="pmid">17414804</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rognmo</surname><given-names>O</given-names></name><name><surname>Hetland</surname><given-names>E</given-names></name><name><surname>Helgerud</surname><given-names>J</given-names></name><name><surname>Hoff</surname><given-names>J</given-names></name><name><surname>Slordahl</surname><given-names>SA</given-names></name></person-group><article-title>High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2004</year><volume>11</volume><issue>3</issue><fpage>216</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1097/01.hjr.0000131677.96762.0c</pub-id><pub-id pub-id-type="pmid">15179103</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, et al. Exercise for depression. Cochrane Database Syst Rev. 2013, Issue 9. Art. No.:CD004366.</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name><name><surname>First</surname><given-names>MB</given-names></name></person-group><article-title>The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description</article-title><source>Arch Gen Psychiatry</source><year>1992</year><volume>49</volume><issue>8</issue><fpage>624</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1992.01820080032005</pub-id><pub-id pub-id-type="pmid">1637252</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heggelund</surname><given-names>J</given-names></name><name><surname>Hoff</surname><given-names>J</given-names></name><name><surname>Helgerud</surname><given-names>J</given-names></name><name><surname>Nilsberg</surname><given-names>GE</given-names></name><name><surname>Morken</surname><given-names>G</given-names></name></person-group><article-title>Reduced peak oxygen uptake and implications for cardiovascular health and quality of life in patients with schizophrenia</article-title><source>BMC Psychiatry</source><year>2011</year><volume>11</volume><fpage>188</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-11-188</pub-id><pub-id pub-id-type="pmid">22142419</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willems</surname><given-names>MET</given-names></name><name><surname>Bond</surname><given-names>TS</given-names></name></person-group><article-title>Comparison of physiological and metabolic responses to playing Nintendo Wii Sports and brisk treadmill walking</article-title><source>J Human Kinet</source><year>2009</year><volume>22</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.2478/v10078-009-0022-5</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>SR</given-names></name><name><surname>Fiszbein</surname><given-names>A</given-names></name><name><surname>Opler</surname><given-names>LA</given-names></name></person-group><article-title>The positive and negative syndrome scale (PANSS) for schizophrenia</article-title><source>Schizophr Bull</source><year>1987</year><volume>13</volume><issue>2</issue><fpage>261</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1093/schbul/13.2.261</pub-id><pub-id pub-id-type="pmid">3616518</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>R</given-names></name><name><surname>Haddock</surname><given-names>G</given-names></name><name><surname>Tarrier</surname><given-names>N</given-names></name><name><surname>Bentall</surname><given-names>R</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name></person-group><article-title>The Psychotic Symptom Rating Scales (PSYRATS): their usefulness and properties in first episode psychosis</article-title><source>Schizophr Res</source><year>2007</year><volume>89</volume><issue>1-3</issue><fpage>119</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2006.04.024</pub-id><pub-id pub-id-type="pmid">17095193</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadwick</surname><given-names>P</given-names></name><name><surname>Birchwood</surname><given-names>M</given-names></name></person-group><article-title>The omnipotence of voices II: The Beliefs About Voices Questionnaire (BAVQ)</article-title><source>Br J Psychiatry</source><year>1995</year><volume>166</volume><issue>6</issue><fpage>773</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1192/bjp.166.6.773</pub-id><pub-id pub-id-type="pmid">7663826</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadwick</surname><given-names>P</given-names></name><name><surname>Lees</surname><given-names>S</given-names></name><name><surname>Birchwood</surname><given-names>M</given-names></name></person-group><article-title>The revised Beliefs About Voices Questionnaire (BAVQ-R)</article-title><source>Br J Psychiatry</source><year>2000</year><volume>177</volume><fpage>229</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1192/bjp.177.3.229</pub-id><pub-id pub-id-type="pmid">11040883</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addington</surname><given-names>D</given-names></name><name><surname>Addington</surname><given-names>J</given-names></name><name><surname>Schissel</surname><given-names>B</given-names></name></person-group><article-title>A depression rating scale for schizophrenics</article-title><source>Schizophr Res</source><year>1990</year><volume>3</volume><issue>4</issue><fpage>247</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/0920-9964(90)90005-R</pub-id><pub-id pub-id-type="pmid">2278986</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addington</surname><given-names>D</given-names></name><name><surname>Addington</surname><given-names>J</given-names></name><name><surname>Maticka-Tyndale</surname><given-names>E</given-names></name><name><surname>Joyce</surname><given-names>J</given-names></name></person-group><article-title>Reliability and validity of a depression rating scale for schizophrenics</article-title><source>Schizophr Res</source><year>1992</year><volume>6</volume><issue>3</issue><fpage>201</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0920-9964(92)90003-N</pub-id><pub-id pub-id-type="pmid">1571313</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>LA</given-names></name><name><surname>Tellegen</surname><given-names>A</given-names></name></person-group><article-title>Development and validation of brief measures of positive and negative affect: the PANAS scales</article-title><source>J Pers Soc Psychol</source><year>1988</year><volume>54</volume><issue>6</issue><fpage>1063</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1037/0022-3514.54.6.1063</pub-id><pub-id pub-id-type="pmid">3397865</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>JR</given-names></name><name><surname>Henry</surname><given-names>JD</given-names></name></person-group><article-title>The positive and negative affect schedule (PANAS): construct validity, measurement properties and normative data in a large non-clinical sample</article-title><source>Br J Clin Psychol</source><year>2004</year><volume>43</volume><issue>Pt 3</issue><fpage>245</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1348/0144665031752934</pub-id><pub-id pub-id-type="pmid">15333231</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><source>National Institute of Mental H, Psychopharmacology Research B, Early Clinical Drug Evaluation P. ECDEU assessment manual for psychopharmacology</source><year>1976</year><publisher-loc>Rockville</publisher-loc><publisher-name>U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs</publisher-name></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krieger</surname><given-names>T</given-names></name><name><surname>Zimmermann</surname><given-names>J</given-names></name><name><surname>Huffziger</surname><given-names>S</given-names></name><name><surname>Ubl</surname><given-names>B</given-names></name><name><surname>Diener</surname><given-names>C</given-names></name><name><surname>Kuehner</surname><given-names>C</given-names></name><etal/></person-group><article-title>Measuring depression with a well-being index: further evidence for the validity of the WHO Well-Being Index (WHO-5) as a measure of the severity of depression</article-title><source>J Affect Disord</source><year>2014</year><volume>156</volume><fpage>240</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2013.12.015</pub-id><pub-id pub-id-type="pmid">24412323</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newnham</surname><given-names>EA</given-names></name><name><surname>Hooke</surname><given-names>GR</given-names></name><name><surname>Page</surname><given-names>AC</given-names></name></person-group><article-title>Monitoring treatment response and outcomes using the World Health Organization&#x02019;s Wellbeing Index in psychiatric care</article-title><source>J Affect Disord</source><year>2010</year><volume>122</volume><issue>1-2</issue><fpage>133</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2009.06.005</pub-id><pub-id pub-id-type="pmid">19592116</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmen</surname><given-names>A</given-names></name><name><surname>Juuhl-Langseth</surname><given-names>M</given-names></name><name><surname>Thormodsen</surname><given-names>R</given-names></name><name><surname>Melle</surname><given-names>I</given-names></name><name><surname>Rund</surname><given-names>BR</given-names></name></person-group><article-title>Neuropsychological profile in early-onset schizophrenia-spectrum disorders: measured with the MATRICS battery</article-title><source>Schizophr Bull</source><year>2010</year><volume>36</volume><issue>4</issue><fpage>852</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbn174</pub-id><pub-id pub-id-type="pmid">19223656</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>RS</given-names></name><name><surname>Penn</surname><given-names>DL</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Horan</surname><given-names>WP</given-names></name><name><surname>Reise</surname><given-names>SP</given-names></name><name><surname>Ochsner</surname><given-names>KN</given-names></name><etal/></person-group><article-title>Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties</article-title><source>Schizophr Bull</source><year>2013</year><volume>39</volume><issue>6</issue><fpage>1201</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbt127</pub-id><pub-id pub-id-type="pmid">24072805</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balke</surname><given-names>B</given-names></name><name><surname>Ware</surname><given-names>RW</given-names></name></person-group><article-title>An experimental study of physical fitness of Air Force personnel</article-title><source>U S Armed Forces Med J</source><year>1959</year><volume>10</volume><issue>6</issue><fpage>675</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">13659732</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faulkner</surname><given-names>G</given-names></name><name><surname>Cohn</surname><given-names>T</given-names></name><name><surname>Remington</surname><given-names>G</given-names></name></person-group><article-title>Validation of a physical activity assessment tool for individuals with schizophrenia</article-title><source>Schizophr Res</source><year>2006</year><volume>82</volume><issue>2-3</issue><fpage>225</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2005.10.020</pub-id><pub-id pub-id-type="pmid">16360305</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>CL</given-names></name><name><surname>Marshall</surname><given-names>AL</given-names></name><name><surname>Sjostrom</surname><given-names>M</given-names></name><name><surname>Bauman</surname><given-names>AE</given-names></name><name><surname>Booth</surname><given-names>ML</given-names></name><name><surname>Ainsworth</surname><given-names>BE</given-names></name><etal/></person-group><article-title>International physical activity questionnaire: 12-country reliability and validity</article-title><source>Med Sci Sports Exerc</source><year>2003</year><volume>35</volume><issue>8</issue><fpage>1381</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1249/01.MSS.0000078924.61453.FB</pub-id><pub-id pub-id-type="pmid">12900694</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>R</given-names></name><name><surname>Schwarzer</surname><given-names>R</given-names></name></person-group><article-title>Selbstwirksamkeit zur sportlichen Aktivit&#x000e4;t: Reliabilit&#x000e4;t und Validit&#x000e4;t eines neuen Me&#x000df;instruments</article-title><source>Zeitschrift f&#x000fc;r differentielle und diagnostische Psychologie</source><year>1994</year><volume>15</volume><issue>3</issue><fpage>141</fpage><lpage>54</lpage></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallis</surname><given-names>JF</given-names></name><name><surname>Grossman</surname><given-names>RM</given-names></name><name><surname>Pinski</surname><given-names>RB</given-names></name><name><surname>Patterson</surname><given-names>TL</given-names></name><name><surname>Nader</surname><given-names>PR</given-names></name></person-group><article-title>The development of scales to measure social support for diet and exercise behaviors</article-title><source>Prev Med</source><year>1987</year><volume>16</volume><issue>6</issue><fpage>825</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/0091-7435(87)90022-3</pub-id><pub-id pub-id-type="pmid">3432232</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Bobick</surname><given-names>TM</given-names></name></person-group><article-title>Integrating the theory of planned behavior with the processes and stages of change in the exercise domain</article-title><source>Psychol Sport Exerc</source><year>2000</year><volume>1</volume><issue>1</issue><fpage>41</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/S1469-0292(00)00006-6</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name></person-group><article-title>The theory of planned behavior and exercise: an investigation into the role of prior behavior, behavioral intentions and attitude variability</article-title><source>Eur J Soc Psychol</source><year>1995</year><volume>25</volume><fpage>403</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1002/ejsp.2420250405</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastien</surname><given-names>CH</given-names></name><name><surname>Valli&#x000e8;res</surname><given-names>A</given-names></name><name><surname>Morin</surname><given-names>CM</given-names></name></person-group><article-title>Validation of the Insomnia Severity Index as an outcome measure for insomnia research</article-title><source>Sleep Med</source><year>2001</year><volume>2</volume><issue>4</issue><fpage>297</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/S1389-9457(00)00065-4</pub-id><pub-id pub-id-type="pmid">11438246</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>JB</given-names></name><name><surname>Aasland</surname><given-names>OG</given-names></name><name><surname>Babor</surname><given-names>TF</given-names></name><name><surname>de la Fuente</surname><given-names>JR</given-names></name><name><surname>Grant</surname><given-names>M</given-names></name></person-group><article-title>Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption &#x02013; II</article-title><source>Addiction</source><year>1993</year><volume>88</volume><issue>6</issue><fpage>791</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.1993.tb02093.x</pub-id><pub-id pub-id-type="pmid">8329970</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>AH</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Palmstierna</surname><given-names>T</given-names></name><name><surname>Schlyter</surname><given-names>F</given-names></name></person-group><article-title>Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample</article-title><source>Eur Addict Res</source><year>2005</year><volume>11</volume><issue>1</issue><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1159/000081413</pub-id><pub-id pub-id-type="pmid">15608468</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLellan</surname><given-names>AT</given-names></name><name><surname>Luborsky</surname><given-names>L</given-names></name><name><surname>Woody</surname><given-names>GE</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>CP</given-names></name></person-group><article-title>An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index</article-title><source>J Nerv Ment Dis</source><year>1980</year><volume>168</volume><issue>1</issue><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1097/00005053-198001000-00006</pub-id><pub-id pub-id-type="pmid">7351540</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>RE</given-names></name><name><surname>Osher</surname><given-names>FC</given-names></name><name><surname>Noordsy</surname><given-names>DL</given-names></name><name><surname>Hurlbut</surname><given-names>SC</given-names></name><name><surname>Teague</surname><given-names>GB</given-names></name><name><surname>Beaudett</surname><given-names>MS</given-names></name></person-group><article-title>Diagnosis of alcohol use disorders in schizophrenia</article-title><source>Schizophr Bull</source><year>1990</year><volume>16</volume><issue>1</issue><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1093/schbul/16.1.57</pub-id><pub-id pub-id-type="pmid">2333482</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mueser</surname><given-names>KT</given-names></name><name><surname>Drake</surname><given-names>RE</given-names></name><name><surname>Clark</surname><given-names>RE</given-names></name><name><surname>McHugo</surname><given-names>GJ</given-names></name><name><surname>Mercer-McFadden</surname><given-names>C</given-names></name><name><surname>Ackerson</surname><given-names>TH</given-names></name></person-group><source>A toolkit for evaluating substance abuse in persons with severe mental illness</source><year>1995</year><publisher-loc>Cambridge</publisher-loc><publisher-name>the Evaluation Center@HSRI</publisher-name></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heatherton</surname><given-names>TF</given-names></name><name><surname>Kozlowski</surname><given-names>LT</given-names></name><name><surname>Frecker</surname><given-names>RC</given-names></name><name><surname>Fagerstrom</surname><given-names>KO</given-names></name></person-group><article-title>The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire</article-title><source>Br J Addict</source><year>1991</year><volume>86</volume><issue>9</issue><fpage>1119</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.1991.tb01879.x</pub-id><pub-id pub-id-type="pmid">1932883</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endicott</surname><given-names>J</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Fleiss</surname><given-names>JL</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance</article-title><source>Arch Gen Psychiatry</source><year>1976</year><volume>33</volume><issue>6</issue><fpage>766</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1976.01770060086012</pub-id><pub-id pub-id-type="pmid">938196</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>G</given-names></name><name><surname>Hagtvet</surname><given-names>KA</given-names></name><name><surname>Karterud</surname><given-names>S</given-names></name></person-group><article-title>Generalizability studies of the Global Assessment of Functioning-Split version</article-title><source>Compr Psychiatry</source><year>2007</year><volume>48</volume><issue>1</issue><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.comppsych.2006.03.008</pub-id><pub-id pub-id-type="pmid">17145287</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birchwood</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Drury</surname><given-names>V</given-names></name><name><surname>Healy</surname><given-names>J</given-names></name><name><surname>Macmillan</surname><given-names>F</given-names></name><name><surname>Slade</surname><given-names>M</given-names></name></person-group><article-title>A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change</article-title><source>Acta Psychiatr Scand</source><year>1994</year><volume>89</volume><issue>1</issue><fpage>62</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1994.tb01487.x</pub-id><pub-id pub-id-type="pmid">7908156</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Baruch</surname><given-names>E</given-names></name><name><surname>Balter</surname><given-names>JM</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name><name><surname>Warman</surname><given-names>DM</given-names></name></person-group><article-title>A new instrument for measuring insight: the Beck Cognitive Insight Scale</article-title><source>Schizophr Res</source><year>2004</year><volume>68</volume><issue>2-3</issue><fpage>319</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S0920-9964(03)00189-0</pub-id><pub-id pub-id-type="pmid">15099613</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>RS</given-names></name><name><surname>Biedrzycki</surname><given-names>RC</given-names></name><name><surname>Firinciogullari</surname><given-names>S</given-names></name></person-group><article-title>Reliability and validity of the Apathy Evaluation Scale</article-title><source>Psychiatry Res</source><year>1991</year><volume>38</volume><issue>2</issue><fpage>143</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(91)90040-V</pub-id><pub-id pub-id-type="pmid">1754629</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group><article-title>CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</article-title><source>Trials</source><year>2010</year><volume>11</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-11-32</pub-id><pub-id pub-id-type="pmid">20334632</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandura</surname><given-names>A</given-names></name></person-group><article-title>Health promotion by social cognitive means</article-title><source>Health Educ Behav</source><year>2004</year><volume>31</volume><issue>2</issue><fpage>143</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1177/1090198104263660</pub-id><pub-id pub-id-type="pmid">15090118</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Martinsen</surname><given-names>EW</given-names></name><name><surname>Stanghelle</surname><given-names>JK</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Morgan</surname><given-names>WP</given-names></name></person-group><article-title>Drug therapy and exercise</article-title><source>Physical activity and mental health</source><year>1997</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>Taylor &#x00026; Francis</publisher-name><fpage>81</fpage><lpage>90</lpage></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thacker</surname><given-names>EL</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>AV</given-names></name><name><surname>McCullough</surname><given-names>ML</given-names></name><name><surname>Calle</surname><given-names>EE</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Recreational physical activity and risk of Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2008</year><volume>23</volume><issue>1</issue><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/mds.21772</pub-id><pub-id pub-id-type="pmid">17960818</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Hollenbeck</surname><given-names>A</given-names></name><name><surname>Blair</surname><given-names>A</given-names></name><name><surname>Schatzkin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Physical activities and future risk of Parkinson disease</article-title><source>Neurology</source><year>2010</year><volume>75</volume><issue>4</issue><fpage>341</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181ea1597</pub-id><pub-id pub-id-type="pmid">20660864</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>AF</given-names></name><name><surname>Hahn</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>NJ</given-names></name><name><surname>Banich</surname><given-names>MT</given-names></name><name><surname>McAuley</surname><given-names>E</given-names></name><name><surname>Harrison</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Ageing, fitness and neurocognitive function</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>418</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/22682</pub-id><pub-id pub-id-type="pmid">10440369</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Fiocco</surname><given-names>AJ</given-names></name><name><surname>Lindquist</surname><given-names>K</given-names></name><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>Simonsick</surname><given-names>EM</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Predictors in maintain cognitive function in older adults: the health ABC study</article-title><source>Neurology</source><year>2009</year><volume>72</volume><issue>23</issue><fpage>2029</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181a92c36</pub-id><pub-id pub-id-type="pmid">19506226</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>H</given-names></name><name><surname>Dan</surname><given-names>I</given-names></name><name><surname>Tsuzuki</surname><given-names>D</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Kyutoku</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Acute moderate exercise elicits increased dorsolateral prefrontal activation and improves cognitive performance with Stroop test</article-title><source>NeuroImage</source><year>2010</year><volume>50</volume><issue>4</issue><fpage>1702</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.12.023</pub-id><pub-id pub-id-type="pmid">20006719</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adcock</surname><given-names>RA</given-names></name><name><surname>Dale</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Aldebot</surname><given-names>S</given-names></name><name><surname>Genevsky</surname><given-names>A</given-names></name><name><surname>Simpson</surname><given-names>GV</given-names></name><etal/></person-group><article-title>When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia</article-title><source>Schizophr Bull</source><year>2009</year><volume>35</volume><issue>6</issue><fpage>1132</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbp068</pub-id><pub-id pub-id-type="pmid">19745022</pub-id></element-citation></ref></ref-list></back></article>